THE NATIVE ANTIGEN COMPANY

Founded in 2010, The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease research reagents. In July of 2020, The Native Antigen Company was acquired by The LGC Group, a global leader in the life sciences sector, and is now part of the LGC Clinical Diagnostics business unit.

ABOUT THE SUPPLIER

Founded in 2010, The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease reagents. Their portfolio of reagents continues to expand rapidly, and they are widely acknowledged to be a primary source of reagents and kits for the study of emerging diseases. In July of 2020, The Native Antigen Company was acquired by The LGC Group, a global leader in the life sciences sector, and is now part of the LGC Clinical Diagnostics business unit.

About LGC Group

Founded in 1842, LGC Group is a leading, global life science tools company, providing mission-critical components and solutions into high-growth application areas across the human healthcare and applied market segments. LGC’s 180+ years of scientific heritage, combined with a track record of innovation and value-enhancing acquisitions, has enabled the company to build its product portfolio and expertise, and develop deep relationships with customers, industry partners and the global scientific community.

The Native Antigen Company (Part of LGC Clinical Diagnostics) has moved to a new state-of-art site in Oxford

On 6 October, 2022, LGC has opened a state-of-the-art facility at the Oxford Technology Park, which will serve both as the new home of The Native Antigen Company (TNAC), part of LGC Clinical Diagnostics, and as the host site of an advanced workflow applications laboratory for LGC Biosearch Technologies.

The laboratory was officially opened by Dame Sarah Gilbert DBE and Teresa Lambe OBE, creators of the Oxford AstraZeneca COVID-19 vaccine.

This new site offers TNAC significantly expanded manufacturing capacity for the production of infectious disease reagents, antibodies and assays, which are vital to the development of clinical diagnostics and the study of infectious diseases.

PRODUCT PORTFOLIOS

The Native Antigen Company offers a range of reagents that enable research into vaccine development and diagnostics for emerging and endemic infectious diseases. Key product ranges include antigens, virus-like particles (VLPs), antibodies, BacTrace® antigens and antibodies, virus receptors, immunoassays, molecular controls, neutralization assay development kits, conjugation kits, and more.

 

FEATURED PRODUCTS

Antigens

The Native Antigen Company produces both native and recombinant antigens for a range of established and emerging viral and bacterial diseases. Their antigens are suitable for use in vaccine R&D, as critical reagents for the development and manufacture of serological diagnostic assays and for fundamental research into infectious diseases. Their HEK293 VirtuE™ expression system is able to introduce proper protein folding and full post-translational modifications, to ensure native-like antigenicity and biological activity.

*All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

Virus-Like Particles (VLPs)

Virus-Like Particles (VLPs) are an emerging technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and while they are highly immunogenic, they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. 

Their cells are expressed in the proprietary human HEK-293 cell line system, which gives the advantage of providing a native like-presentation. Each recombinant VLP consists of 180 copies of E protein combined with prM/M protein to form a viral particle.

*All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

Antibodies

They are developing one of the world’s most extensive range of antibodies for infectious disease targets. Their portfolio includes a range of coronavirus antibodies, as well as a panel of highly specific antibodies for flavivirus NS1 proteins, such as serotype-specific reagents for Dengue and human chimeric Zika NS1 monoclonals.

*All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

BacTrace® Antigens and Antibodies

BacTrace® comprises KPL’s range of native bacterial antigens and matching primary antibodies. Produced in an ISO13485-certified facility, BacTrace bacterial antigens are grown as whole cells in native culture. BacTrace antibodies are generated by inoculating goats with BacTrace bacterial antigens. The resulting polyclonal sera then undergoes a proprietary affinity purification protocol that preserves target antigen affinity while yielding fractions that are highly specific to the pathogen in question. Combined with downstream cross-reactivity testing, BacTrace antibodies benefit from maximal signal-to-noise ratio, while ensuring defined specificity and lot-to-lot consistency.

*All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

Virus Receptors

The Native Antigen Company is developing a range of virus receptors for use in studying the interaction of viruses with their target cells. These reagents may be used in the development on in vitro assays for investigating potential methods to block virus-to-cell binding.

*All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

Conjugation kits

The Native Antigen Company provides a range of conjugation kits that utilize a novel chemistry to generate highly reproducible conjugates.

*All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

FURTHER READING

 

  • Flavivirus research
  • Vector-borne Bunyaviridae research
  • Influenza research
  • Featured products from The Native Antigen Company

Learn more on our reagents and kits for emerging diseases research.

Contact us